Core Viewpoint - WuXi AppTec reported significant growth in revenue and net profit for the first three quarters of 2025, driven by its focus on the CRDMO business model and operational efficiency improvements [1][3]. Financial Performance - For the first three quarters of 2025, WuXi AppTec achieved operating revenue of RMB 32.857 billion, a year-on-year increase of 18.61% [1]. - The net profit attributable to shareholders reached RMB 12.076 billion, reflecting a substantial year-on-year growth of 84.84% [1][2]. - As of September 30, 2025, the company had a backlog of orders amounting to RMB 59.88 billion, up 41.2% year-on-year [2]. Revenue Breakdown - Revenue from continuous operations for the first three quarters was RMB 32.45 billion, with contributions from various regions: - Revenue from U.S. clients: RMB 22.15 billion, up 31.9% - Revenue from European clients: RMB 3.84 billion, up 13.5% - Revenue from Chinese clients: RMB 5.04 billion, up 0.5% - Revenue from other regions: RMB 1.42 billion, up 9.2% [2]. - The chemical business generated RMB 25.98 billion, a growth of 29.3% [2]. Strategic Moves - WuXi AppTec announced the sale of 100% equity in two subsidiaries for a base price of RMB 2.8 billion to a company under Hillhouse Capital [4]. - The divestiture aligns with the company's strategy to focus on its core CRDMO business, enhancing its global capabilities and operational capacity [4][5]. Future Outlook - The company expects continuous operations revenue growth to return to double digits, with an adjusted growth rate forecast of 17-18% [3]. - Overall revenue guidance for the year has been raised to between RMB 43.5 billion and RMB 44 billion [3].
药明康德前三季度净利润超120亿元